Drug Trial Radar · NCT04822376
Prophylaxis Vaccine Antibodies Ebola
Last checked: Nov 20, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 17, 2021
Primary completion
Apr 2022
Study completion Apr 2022
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Mar 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
* Three measures are currently being implemented to control Ebola outbreaks: * Monitoring of contacts * Isolation and treatment of sick people * Vaccination of the population in high-risk areas. * In contacts with high viral exposure and therefore a high risk of incubation and rapid expression of infection, the r-VSV-ZEBOV vaccine does not provide adequate protection because vaccine antibody production is effective 6 to 10 days after administration. * Specific monoclonal antibodies (Mab) from the Regeneron and mAb114 research specialties have been shown to be effective in reducing mortality in patients with Ebola virus disease (EVD). * Their use in a single parenteral administration and good tolerability make them candidates for use in post-exposure prophylaxis (PEP) in individuals at high risk of viral exposure. * A comprehensive strategy for the protection of high-risk contacts must therefore be implemented, including the vaccine and the Mabs, to ensure both immediate and prolonged protection. Indeed, the efficacy of the vaccine is likely to be diminished when co-administered with Mabs, as both strategies share the same viral target (the GP envelope glycoprotein) and the vaccine is replicative (and therefore may be inhibited by Mabs). PROVAE aim to evaluate the effectiveness of a comprehensive strategy to prevent transmission of MVE in contacts at high risk of infection, including (i) post-exposure prophylaxis with Mabs and (ii) vaccination with r-VSV-ZEBOV.
Conditions
- Ebola Virus Disease
Interventions
ansuvimabDrug
Human monoclonal antibody to Zaire strain GP (EBOV GP)
ErveboBiological
Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- EfficacyTime frame: Week 3
- Immunological ancillary studyTime frame: 6 months after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de Traitement Ebola de N'Zerekore
N'Zerekore, Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.